{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:30:45Z","timestamp":1768444245623,"version":"3.49.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T00:00:00Z","timestamp":1484784000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100008486","name":"Swiss Multiple Sclerosis Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008486","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008241","name":"Desir\u00e9e og Niels Ydes Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008475","name":"Hartmann-M\u00fcller Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008475","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s40263-017-0407-2","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T21:42:23Z","timestamp":1484862143000},"page":"187-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Nogo-A Antibodies for Progressive Multiple Sclerosis"],"prefix":"10.1007","volume":"31","author":[{"given":"Benjamin V.","family":"Ineichen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia S.","family":"Plattner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Good","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Linnebank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E.","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,19]]},"reference":[{"key":"407_CR1","first-page":"13","volume-title":"Multiple Sclerosis International Federation. Atlas: Multiple Sclerosis Resources in the World 2008","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. Multiple Sclerosis International Federation. Atlas: Multiple Sclerosis Resources in the World 2008. Geneva: World Health Organization; 2008. p. 13\u20137."},{"key":"407_CR2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","volume":"31","author":"BD Trapp","year":"2008","unstructured":"Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247\u201369.","journal-title":"Annu Rev Neurosci"},{"issue":"7359","key":"407_CR3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"S Sawcer","year":"2011","unstructured":"Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214\u20139.","journal-title":"Nature"},{"issue":"Pt 5","key":"407_CR4","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/brain\/awp106","volume":"132","author":"EC Tallantyre","year":"2009","unstructured":"Tallantyre EC, Bo L, Al-Rawashdeh O, et al. Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain. 2009;132(Pt 5):1190\u20139.","journal-title":"Brain"},{"issue":"11","key":"407_CR5","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1177\/1352458512458169","volume":"18","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Thompson A, Baker D, et al. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler (Houndmills, Basingstoke, England). 2012;18(11):1534\u201340.","journal-title":"Mult Scler (Houndmills, Basingstoke, England)"},{"issue":"Suppl. 1","key":"407_CR6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.12883","volume":"23","author":"O Torkildsen","year":"2016","unstructured":"Torkildsen O, Myhr KM, Bo L. Disease-modifying treatments for multiple sclerosis: a review of approved medications. Eur J Neurol. 2016;23(Suppl. 1):18\u201327.","journal-title":"Eur J Neurol"},{"issue":"1","key":"407_CR7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","volume":"253","author":"AJ Coles","year":"2006","unstructured":"Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253(1):98\u2013108.","journal-title":"J Neurol"},{"issue":"3","key":"407_CR8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ana.24009","volume":"74","author":"SL Hauser","year":"2013","unstructured":"Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: prospects and promise. Ann Neurol. 2013;74(3):317\u201327.","journal-title":"Ann Neurol"},{"issue":"11","key":"407_CR9","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1212\/WNL.57.11.1969","volume":"57","author":"L Kappos","year":"2001","unstructured":"Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology. 2001;57(11):1969\u201375.","journal-title":"Neurology"},{"issue":"9350","key":"407_CR10","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"HP Hartung","year":"2002","unstructured":"Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018\u201325.","journal-title":"Lancet"},{"issue":"15","key":"407_CR11","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","volume":"373","author":"L Kappos","year":"2015","unstructured":"Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373(15):1418\u201328.","journal-title":"N Engl J Med"},{"issue":"9884","key":"407_CR12","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","volume":"381","author":"R Gold","year":"2013","unstructured":"Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9884):2167\u201375.","journal-title":"Lancet"},{"issue":"16 Suppl.","key":"407_CR13","doi-asserted-by":"crossref","first-page":"S49-001","DOI":"10.1212\/WNL.86.16_supplement.S49.001","volume":"86","author":"X Montalban","year":"2016","unstructured":"Montalban X, Hemmer B, Rammohan K, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis: results of the phase III double-blind, placebo-controlled ORATORIO study (S49.001). Neurology. 2016;86(16 Suppl.):S49-001.","journal-title":"Neurology."},{"key":"407_CR14","unstructured":"Hauser S, Comi G, Hartung H-P, et al. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double-blind, phase III OPERA I and II studies. Mult Scler. 2015;61\u20132."},{"issue":"1","key":"407_CR15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14740338.2017.1250881","volume":"16","author":"MP McGinley","year":"2017","unstructured":"McGinley MP, Moss BP, Cohen JA. Safety of monoclonal antibodies for the treatment of multiple sclerosis. Exp Opin Drug Saf. 2017;16(1):89\u2013100.","journal-title":"Exp Opin Drug Saf"},{"issue":"2","key":"407_CR16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1474-4422(14)70264-9","volume":"14","author":"D Ontaneda","year":"2015","unstructured":"Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14(2):208\u201323.","journal-title":"Lancet Neurol"},{"issue":"3","key":"407_CR17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrneurol.2015.14","volume":"11","author":"RM Ransohoff","year":"2015","unstructured":"Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis: a quiet revolution. Nat Rev Neurol. 2015;11(3):134\u201342.","journal-title":"Nat Rev Neurol"},{"key":"407_CR18","doi-asserted-by":"publisher","unstructured":"Lassmann H, Bradl M. Multiple sclerosis: experimental models and reality. Acta Neuropathol. 2016. doi: 10.1007\/s00401-016-1631-4 .","DOI":"10.1007\/s00401-016-1631-4"},{"issue":"1","key":"407_CR19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13311-015-0409-z","volume":"13","author":"A Shirani","year":"2016","unstructured":"Shirani A, Okuda DT, Stuve O. Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics. 2016;13(1):58\u201369.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"407_CR20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"BD Trapp","year":"1998","unstructured":"Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278\u201385.","journal-title":"N Engl J Med"},{"issue":"3","key":"407_CR21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/WCO.0b013e328346056f","volume":"24","author":"C Stadelmann","year":"2011","unstructured":"Stadelmann C. Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr Opin Neurol. 2011;24(3):224\u20139.","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"407_CR22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-2008-1040881","volume":"18","author":"BG Weinshenker","year":"1998","unstructured":"Weinshenker BG. The natural history of multiple sclerosis: update 1998. Semin Neurol. 1998;18(3):301\u20137.","journal-title":"Semin Neurol"},{"issue":"12","key":"407_CR23","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archneurol.2011.914","volume":"68","author":"M Filippi","year":"2011","unstructured":"Filippi M, Rocca MA, De Stefano N, et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol. 2011;68(12):1514\u201320.","journal-title":"Arch Neurol"},{"key":"407_CR24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/B978-0-444-52001-2.00005-4","volume":"122","author":"G Criste","year":"2014","unstructured":"Criste G, Trapp B, Dutta R. Axonal loss in multiple sclerosis: causes and mechanisms. Handb Clin Neurol. 2014;122:101\u201313.","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"407_CR25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","volume":"14","author":"DH Mahad","year":"2015","unstructured":"Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183\u201393.","journal-title":"Lancet Neurol"},{"issue":"Pt 3","key":"407_CR26","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/brain\/aws012","volume":"135","author":"MT Fischer","year":"2012","unstructured":"Fischer MT, Sharma R, Lim JL, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain. 2012;135(Pt 3):886\u201399.","journal-title":"Brain"},{"issue":"2","key":"407_CR27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00401-012-1001-9","volume":"124","author":"GR Campbell","year":"2012","unstructured":"Campbell GR, Kraytsberg Y, Krishnan KJ, et al. Clonally expanded mitochondrial DNA deletions within the choroid plexus in multiple sclerosis. Acta Neuropathol. 2012;124(2):209\u201320.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"407_CR28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molmed.2013.11.007","volume":"20","author":"ME Witte","year":"2014","unstructured":"Witte ME, Mahad DJ, Lassmann H, van Horssen J. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med. 2014;20(3):179\u201387.","journal-title":"Trends Mol Med"},{"issue":"9","key":"407_CR29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545\u201358.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"407_CR30","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.neuron.2014.11.006","volume":"84","author":"CD Sorbara","year":"2014","unstructured":"Sorbara CD, Wagner NE, Ladwig A, et al. Pervasive axonal transport deficits in multiple sclerosis models. Neuron. 2014;84(6):1183\u201390.","journal-title":"Neuron"},{"issue":"6","key":"407_CR31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ana.24006","volume":"74","author":"AL Davies","year":"2013","unstructured":"Davies AL, Desai RA, Bloomfield PS, et al. Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann Neurol. 2013;74(6):815\u201325.","journal-title":"Ann Neurol"},{"issue":"4","key":"407_CR32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.24607","volume":"79","author":"RA Desai","year":"2016","unstructured":"Desai RA, Davies AL, Tachrount M, et al. Cause and prevention of demyelination in a model multiple sclerosis lesion. Ann Neurol. 2016;79(4):591\u2013604.","journal-title":"Ann Neurol"},{"issue":"4","key":"407_CR33","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ana.24632","volume":"79","author":"H Lassmann","year":"2016","unstructured":"Lassmann H. Demyelination and neurodegeneration in multiple sclerosis: the role of hypoxia. Ann Neurol. 2016;79(4):520\u20131.","journal-title":"Ann Neurol"},{"issue":"3","key":"407_CR34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2990.2007.00805.x","volume":"33","author":"R Patani","year":"2007","unstructured":"Patani R, Balaratnam M, Vora A, Reynolds R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol Appl Neurobiol. 2007;33(3):277\u201387.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"11","key":"407_CR35","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/glia.22622","volume":"62","author":"RJ Franklin","year":"2014","unstructured":"Franklin RJ, Gallo V. The translational biology of remyelination: past, present, and future. Glia. 2014;62(11):1905\u201315.","journal-title":"Glia"},{"issue":"7321","key":"407_CR36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nature09614","volume":"468","author":"KA Nave","year":"2010","unstructured":"Nave KA. Myelination and support of axonal integrity by glia. Nature. 2010;468(7321):244\u201352.","journal-title":"Nature"},{"issue":"11","key":"407_CR37","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrneurol.2012.200","volume":"8","author":"RJ Franklin","year":"2012","unstructured":"Franklin RJ, Ffrench-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol. 2012;8(11):624\u201334.","journal-title":"Nat Rev Neurol"},{"issue":"21","key":"407_CR38","doi-asserted-by":"crossref","first-page":"8168","DOI":"10.1073\/pnas.0402765101","volume":"101","author":"MJ Craner","year":"2004","unstructured":"Craner MJ, Newcombe J, Black JA, et al. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+\/Ca2+ exchanger. Proc Natl Acad Sci USA. 2004;101(21):8168\u201373.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"Pt 2","key":"407_CR39","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/brain\/awq337","volume":"134","author":"S Vergo","year":"2011","unstructured":"Vergo S, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain. 2011;134(Pt 2):571\u201384.","journal-title":"Brain."},{"issue":"12","key":"407_CR40","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/nm1668","volume":"13","author":"MA Friese","year":"2007","unstructured":"Friese MA, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med. 2007;13(12):1483\u20139.","journal-title":"Nat Med"},{"issue":"12","key":"407_CR41","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/nm.3015","volume":"18","author":"B Schattling","year":"2012","unstructured":"Schattling B, Steinbach K, Thies E, et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2012;18(12):1805\u201311.","journal-title":"Nat Med"},{"issue":"4","key":"407_CR42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","volume":"10","author":"MA Friese","year":"2014","unstructured":"Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 2014;10(4):225\u201338.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"407_CR43","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.24497","volume":"78","author":"JM Frischer","year":"2015","unstructured":"Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710\u201321.","journal-title":"Ann Neurol"},{"issue":"2","key":"407_CR44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/135245859800400203","volume":"4","author":"I Mews","year":"1998","unstructured":"Mews I, Bergmann M, Bunkowski S, et al. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler. 1998;4(2):55\u201362.","journal-title":"Mult Scler"},{"issue":"6","key":"407_CR45","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B","volume":"48","author":"C Bjartmar","year":"2000","unstructured":"Bjartmar C, Kidd G, Mork S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000;48(6):893\u2013901.","journal-title":"Ann Neurol"},{"key":"407_CR46","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","volume":"23","author":"M Sospedra","year":"2005","unstructured":"Sospedra M, Martin R. Immunology of multiple sclerosis. Ann Rev Immunol. 2005;23:683\u2013747.","journal-title":"Ann Rev Immunol"},{"issue":"1","key":"407_CR47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neuron.2005.09.004","volume":"48","author":"M Dubois-Dalcq","year":"2005","unstructured":"Dubois-Dalcq M, Ffrench-Constant C, Franklin RJ. Enhancing central nervous system remyelination in multiple sclerosis. Neuron. 2005;48(1):9\u201312.","journal-title":"Neuron"},{"issue":"8","key":"407_CR48","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1007\/s12035-015-9436-3","volume":"53","author":"B Wootla","year":"2016","unstructured":"Wootla B, Denic A, Watzlawik JO, et al. Antibody-mediated oligodendrocyte remyelination promotes axon health in progressive demyelinating disease. Mol Neurobiol. 2016;53(8):5217\u201328.","journal-title":"Mol Neurobiol"},{"issue":"12","key":"407_CR49","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nrn2936","volume":"11","author":"ME Schwab","year":"2010","unstructured":"Schwab ME. Functions of Nogo proteins and their receptors in the nervous system. Nat Rev Neurosci. 2010;11(12):799\u2013811.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"407_CR50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0896-6273(88)90212-7","volume":"1","author":"P Caroni","year":"1988","unstructured":"Caroni P, Schwab ME. Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron. 1988;1(1):85\u201396.","journal-title":"Neuron"},{"issue":"6768","key":"407_CR51","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/35000226","volume":"403","author":"T GrandPre","year":"2000","unstructured":"GrandPre T, Nakamura F, Vartanian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a reticulon protein. Nature. 2000;403(6768):439\u201344.","journal-title":"Nature"},{"issue":"6768","key":"407_CR52","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/35000219","volume":"403","author":"MS Chen","year":"2000","unstructured":"Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature. 2000;403(6768):434\u20139.","journal-title":"Nature"},{"key":"407_CR53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.conb.2014.02.011","volume":"27","author":"ME Schwab","year":"2014","unstructured":"Schwab ME, Strittmatter SM. Nogo limits neural plasticity and recovery from injury. Curr Opin Neurobiol. 2014;27:53\u201360.","journal-title":"Curr Opin Neurobiol"},{"issue":"9","key":"407_CR54","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1523\/JNEUROSCI.22-09-03553.2002","volume":"22","author":"AB Huber","year":"2002","unstructured":"Huber AB, Weinmann O, Brosamle C, et al. Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J Neurosci. 2002;22(9):3553\u201367.","journal-title":"J Neurosci"},{"issue":"13","key":"407_CR55","doi-asserted-by":"crossref","first-page":"12494","DOI":"10.1074\/jbc.M411827200","volume":"280","author":"DA Dodd","year":"2005","unstructured":"Dodd DA, Niederoest B, Bloechlinger S, et al. Nogo-A, -B, and -C are found on the cell surface and interact together in many different cell types. J Biol Chem. 2005;280(13):12494\u2013502.","journal-title":"J Biol Chem"},{"issue":"6892","key":"407_CR56","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nature00867","volume":"417","author":"KC Wang","year":"2002","unstructured":"Wang KC, Koprivica V, Kim JA, et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature. 2002;417(6892):941\u20134.","journal-title":"Nature"},{"issue":"3","key":"407_CR57","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12035-009-8083-y","volume":"40","author":"M Nash","year":"2009","unstructured":"Nash M, Pribiag H, Fournier AE, Jacobson C. Central nervous system regeneration inhibitors and their intracellular substrates. Mol Neurobiol. 2009;40(3):224\u201335.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"407_CR58","doi-asserted-by":"crossref","first-page":"e1001763","DOI":"10.1371\/journal.pbio.1001763","volume":"12","author":"A Kempf","year":"2014","unstructured":"Kempf A, Tews B, Arzt ME, et al. The sphingolipid receptor S1PR2 is a receptor for Nogo-a repressing synaptic plasticity. PLoS Biol. 2014;12(1):e1001763.","journal-title":"PLoS Biol"},{"issue":"16","key":"407_CR59","doi-asserted-by":"crossref","first-page":"10793","DOI":"10.1074\/jbc.M808297200","volume":"284","author":"L Montani","year":"2009","unstructured":"Montani L, Gerrits B, Gehrig P, et al. Neuronal Nogo-A modulates growth cone motility via Rho-GTP\/LIMK1\/cofilin in the unlesioned adult nervous system. J Biol Chem. 2009;284(16):10793\u2013807.","journal-title":"J Biol Chem"},{"issue":"11","key":"407_CR60","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3109\/02699052.2013.812241","volume":"27","author":"X Gou","year":"2013","unstructured":"Gou X, Zhang Q, Xu N, et al. Spatio-temporal expression of paired immunoglobulin-like receptor-B in the adult mouse brain after focal cerebral ischaemia. Brain Inj. 2013;27(11):1311\u20135.","journal-title":"Brain Inj"},{"issue":"7","key":"407_CR61","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40263-013-0068-8","volume":"27","author":"S Mi","year":"2013","unstructured":"Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013;27(7):493\u2013503.","journal-title":"CNS Drugs"},{"issue":"4","key":"407_CR62","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.mcn.2006.12.004","volume":"34","author":"B Barrette","year":"2007","unstructured":"Barrette B, Vallieres N, Dube M, Lacroix S. Expression profile of receptors for myelin-associated inhibitors of axonal regeneration in the intact and injured mouse central nervous system. Mol Cell Neurosci. 2007;34(4):519\u201338.","journal-title":"Mol Cell Neurosci"},{"key":"407_CR63","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fnins.2014.00338","volume":"8","author":"Y Fujita","year":"2014","unstructured":"Fujita Y, Yamashita T. Axon growth inhibition by RhoA\/ROCK in the central nervous system. Frontiers Neurosci. 2014;8:338.","journal-title":"Frontiers Neurosci"},{"issue":"4","key":"407_CR64","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1471-4159.2005.03238.x","volume":"94","author":"FY Teng","year":"2005","unstructured":"Teng FY, Tang BL. Why do Nogo\/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents? J Neurochem. 2005;94(4):865\u201374.","journal-title":"J Neurochem"},{"issue":"5","key":"407_CR65","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.neuron.2010.05.002","volume":"66","author":"JK Lee","year":"2010","unstructured":"Lee JK, Geoffroy CG, Chan AF, et al. Assessing spinal axon regeneration and sprouting in Nogo-, MAG-, and OMgp-deficient mice. Neuron. 2010;66(5):663\u201370.","journal-title":"Neuron"},{"issue":"4","key":"407_CR66","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/1073858413516800","volume":"20","author":"A Schmandke","year":"2014","unstructured":"Schmandke A, Schmandke A, Schwab ME. Nogo-A: multiple roles in CNS development, maintenance, and disease. Neuroscientist. 2014;20(4):372\u201386.","journal-title":"Neuroscientist"},{"issue":"4","key":"407_CR67","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1073\/pnas.1113540109","volume":"109","author":"SY Chong","year":"2012","unstructured":"Chong SY, Rosenberg SS, Fancy SP, et al. Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of oligodendrocyte myelination. Proc Natl Acad Sci USA. 2012;109(4):1299\u2013304.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"407_CR68","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/neu.2011.1752","volume":"29","author":"RR Gonzenbach","year":"2012","unstructured":"Gonzenbach RR, Zoerner B, Schnell L, et al. Delayed anti-nogo-a antibody application after spinal cord injury shows progressive loss of responsiveness. J Neurotrauma. 2012;29(3):567\u201378.","journal-title":"J Neurotrauma"},{"issue":"5","key":"407_CR69","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/ana.22527","volume":"70","author":"X Wang","year":"2011","unstructured":"Wang X, Duffy P, McGee AW, et al. Recovery from chronic spinal cord contusion after Nogo receptor intervention. Ann Neurol. 2011;70(5):805\u201321.","journal-title":"Ann Neurol"},{"issue":"1","key":"407_CR70","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/STROKEAHA.110.590083","volume":"42","author":"SY Tsai","year":"2011","unstructured":"Tsai SY, Papadopoulos CM, Schwab ME, Kartje GL. Delayed anti-nogo-a therapy improves function after chronic stroke in adult rats. Stroke. 2011;42(1):186\u201390.","journal-title":"Stroke"},{"issue":"6","key":"407_CR71","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.20676","volume":"58","author":"TM Markus","year":"2005","unstructured":"Markus TM, Tsai SY, Bollnow MR, et al. Recovery and brain reorganization after stroke in adult and aged rats. Ann Neurol. 2005;58(6):950\u20133.","journal-title":"Ann Neurol"},{"issue":"6189","key":"407_CR72","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1126\/science.1253050","volume":"344","author":"AS Wahl","year":"2014","unstructured":"Wahl AS, Omlor W, Rubio JC, et al. Neuronal repair. Asynchronous therapy restores motor control by rewiring of the rat corticospinal tract after stroke. Science (New York, NY). 2014;344(6189):1250\u20135.","journal-title":"Science (New York, NY)"},{"issue":"7","key":"407_CR73","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nm1436","volume":"12","author":"P Freund","year":"2006","unstructured":"Freund P, Schmidlin E, Wannier T, et al. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat Med. 2006;12(7):790\u20132.","journal-title":"Nat Med"},{"issue":"40","key":"407_CR74","doi-asserted-by":"crossref","first-page":"13220","DOI":"10.1523\/JNEUROSCI.1044-10.2010","volume":"30","author":"M Zagrebelsky","year":"2010","unstructured":"Zagrebelsky M, Schweigreiter R, Bandtlow CE, et al. Nogo-A stabilizes the architecture of hippocampal neurons. J Neurosci. 2010;30(40):13220\u201334.","journal-title":"J Neurosci"},{"issue":"6","key":"407_CR75","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.1013322108","volume":"108","author":"A Delekate","year":"2011","unstructured":"Delekate A, Zagrebelsky M, Kramer S, et al. NogoA restricts synaptic plasticity in the adult hippocampus on a fast time scale. Proc Natl Acad Sci. 2011;108(6):2569\u201374.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"407_CR76","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tins.2013.04.003","volume":"36","author":"YA Mironova","year":"2013","unstructured":"Mironova YA, Giger RJ. Where no synapses go: gatekeepers of circuit remodeling and synaptic strength. Trends Neurosci. 2013;36(6):363\u201373.","journal-title":"Trends Neurosci"},{"issue":"26","key":"407_CR77","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.1523\/JNEUROSCI.3817-13.2014","volume":"34","author":"A Zemmar","year":"2014","unstructured":"Zemmar A, Weinmann O, Kellner Y, et al. Neutralization of Nogo-A enhances synaptic plasticity in the rodent motor cortex and improves motor learning in vivo. J Neurosci. 2014;34(26):8685\u201398.","journal-title":"J Neurosci"},{"issue":"3","key":"407_CR78","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.neuron.2011.11.029","volume":"73","author":"ZP Wills","year":"2012","unstructured":"Wills ZP, Mandel-Brehm C, Mardinly AR, et al. The nogo receptor family restricts synapse number in the developing hippocampus. Neuron. 2012;73(3):466\u201381.","journal-title":"Neuron"},{"issue":"4","key":"407_CR79","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/1073858413477207","volume":"19","author":"JY Lee","year":"2013","unstructured":"Lee JY, Petratos S. Multiple sclerosis: does Nogo play a role? Neuroscientist. 2013;19(4):394\u2013408.","journal-title":"Neuroscientist"},{"issue":"7","key":"407_CR80","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nn1261","volume":"7","author":"T Karnezis","year":"2004","unstructured":"Karnezis T, Mandemakers W, McQualter JL, et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci. 2004;7(7):736\u201344.","journal-title":"Nat Neurosci"},{"issue":"11","key":"407_CR81","doi-asserted-by":"crossref","first-page":"6981","DOI":"10.4049\/jimmunol.173.11.6981","volume":"173","author":"P Fontoura","year":"2004","unstructured":"Fontoura P, Ho PP, DeVoss J, et al. Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis. J Immunol. 2004;173(11):6981\u201392.","journal-title":"J Immunol"},{"issue":"1\u20132","key":"407_CR82","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jns.2005.07.020","volume":"245","author":"P Fontoura","year":"2006","unstructured":"Fontoura P, Steinman L. Nogo in multiple sclerosis: growing roles of a growth inhibitor. Journal of the neurological sciences. J Neurol Sci. 2006;245(1\u20132):201\u201310.","journal-title":"J Neurol Sci"},{"issue":"Pt 6","key":"407_CR83","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/brain\/aws100","volume":"135","author":"S Petratos","year":"2012","unstructured":"Petratos S, Ozturk E, Azari MF, et al. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012;135(Pt 6):1794\u2013818.","journal-title":"Brain"},{"issue":"4","key":"407_CR84","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/ana.21935","volume":"67","author":"Y Yang","year":"2010","unstructured":"Yang Y, Liu Y, Wei P, et al. Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann Neurol. 2010;67(4):498\u2013507.","journal-title":"Ann Neurol"},{"issue":"4","key":"407_CR85","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nm.2324","volume":"17","author":"I Nikic","year":"2011","unstructured":"Nikic I, Merkler D, Sorbara C, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2011;17(4):495\u20139.","journal-title":"Nat Med"},{"issue":"7","key":"407_CR86","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/hbm.23184","volume":"37","author":"V Tomassini","year":"2016","unstructured":"Tomassini V, d\u2019Ambrosio A, Petsas N, et al. The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence. Hum Brain Mapp. 2016;37(7):2431\u201345.","journal-title":"Hum Brain Mapp"},{"issue":"3","key":"407_CR87","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nn1195","volume":"7","author":"FM Bareyre","year":"2004","unstructured":"Bareyre FM, Kerschensteiner M, Raineteau O, et al. The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. Nat Neurosci. 2004;7(3):269\u201377.","journal-title":"Nat Neurosci"},{"issue":"8","key":"407_CR88","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.20040452","volume":"200","author":"M Kerschensteiner","year":"2004","unstructured":"Kerschensteiner M, Bareyre FM, Buddeberg BS, et al. Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J Exp Med. 2004;200(8):1027\u201338.","journal-title":"J Exp Med"},{"issue":"10","key":"407_CR89","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/NEN.0b013e31826caebe","volume":"71","author":"P Theotokis","year":"2012","unstructured":"Theotokis P, Lourbopoulos A, Touloumi O, et al. Time course and spatial profile of Nogo-A expression in experimental autoimmune encephalomyelitis in C57BL\/6 mice. J Neuropathol Exp Neurol. 2012;71(10):907\u201320.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Pt 7","key":"407_CR90","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/brain\/awn119","volume":"131","author":"JM Anderson","year":"2008","unstructured":"Anderson JM, Hampton DW, Patani R, et al. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain. 2008;131(Pt 7):1736\u201348.","journal-title":"Brain"},{"issue":"1","key":"407_CR91","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pathophys.2010.04.004","volume":"18","author":"A Denic","year":"2011","unstructured":"Denic A, Johnson AJ, Bieber AJ, et al. The relevance of animal models in multiple sclerosis research. Pathophysiology. 2011;18(1):21\u20139.","journal-title":"Pathophysiology"},{"issue":"6","key":"407_CR92","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1523\/JNEUROSCI.4645-04.2005","volume":"25","author":"C Jaillard","year":"2005","unstructured":"Jaillard C, Harrison S, Stankoff B, et al. Edg8\/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci. 2005;25(6):1459\u201369.","journal-title":"J Neurosci"},{"issue":"29","key":"407_CR93","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.1523\/JNEUROSCI.0727-08.2008","volume":"28","author":"V Pernet","year":"2008","unstructured":"Pernet V, Joly S, Christ F, et al. Nogo-A and myelin-associated glycoprotein differently regulate oligodendrocyte maturation and myelin formation. J Neurosci. 2008;28(29):7435\u201344.","journal-title":"J Neurosci"},{"issue":"3\u20134","key":"407_CR94","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.3171\/FOC\/2008\/24\/3-4\/E4","volume":"24","author":"YA Syed","year":"2008","unstructured":"Syed YA, Baer AS, Lubec G, et al. Inhibition of oligodendrocyte precursor cell differentiation by myelin-associated proteins. Neurosurg Focus. 2008;24(3\u20134):E5.","journal-title":"Neurosurg Focus"},{"issue":"6","key":"407_CR95","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nn1460","volume":"8","author":"S Mi","year":"2005","unstructured":"Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8(6):745\u201351.","journal-title":"Nat Neurosci"},{"issue":"10","key":"407_CR96","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/nm1664","volume":"13","author":"S Mi","year":"2007","unstructured":"Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13(10):1228\u201333.","journal-title":"Nat Med"},{"issue":"3","key":"407_CR97","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.21581","volume":"65","author":"S Mi","year":"2009","unstructured":"Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol. 2009;65(3):304\u201315.","journal-title":"Ann Neurol"},{"issue":"1","key":"407_CR98","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1523\/JNEUROSCI.4175-06.2007","volume":"27","author":"X Lee","year":"2007","unstructured":"Lee X, Yang Z, Shao Z, et al. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J Neurosci. 2007;27(1):220\u20135.","journal-title":"J Neurosci"},{"issue":"11","key":"407_CR99","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaneurol.2015.2188","volume":"72","author":"B Wootla","year":"2015","unstructured":"Wootla B, Watzlawik JO, Warrington AE, et al. Naturally occurring monoclonal antibodies and their therapeutic potential for neurologic diseases. JAMA Neurol. 2015;72(11):1346\u201353.","journal-title":"JAMA Neurol"},{"issue":"2","key":"407_CR100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnen\/64.2.129","volume":"64","author":"J Satoh","year":"2005","unstructured":"Satoh J, Onoue H, Arima K, Yamamura T. Nogo-A and nogo receptor expression in demyelinating lesions of multiple sclerosis. J Neuropathol Exp Neurol. 2005;64(2):129\u201338.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1\u20132","key":"407_CR101","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jneuroim.2003.09.010","volume":"145","author":"M Reindl","year":"2003","unstructured":"Reindl M, Khantane S, Ehling R, et al. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J Neuroimmunol. 2003;145(1\u20132):139\u201347.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"407_CR102","doi-asserted-by":"crossref","first-page":"e97803","DOI":"10.1371\/journal.pone.0097803","volume":"9","author":"V Meininger","year":"2014","unstructured":"Meininger V, Pradat PF, Corse A, et al. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial. PLoS One. 2014;9(5):e97803.","journal-title":"PLoS One"},{"issue":"2","key":"407_CR103","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1212\/NXI.0000000000000018","volume":"1","author":"JQ Tran","year":"2014","unstructured":"Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety\/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014;1(2):e18.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"407_CR104","doi-asserted-by":"crossref","unstructured":"Cadavid D, Balcer L, Galetta S, et al. Evidence of remyelination with the anti-LINGO-1 monoclonal antibody BIIB033 after acute optic neuritis. Neurology. 2015; E46.","DOI":"10.1212\/WNL.84.14_supplement.P7.202"},{"issue":"6","key":"407_CR105","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1212\/WNL.40.6.971","volume":"40","author":"JH Noseworthy","year":"1990","unstructured":"Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial: the Canadian Cooperation MS Study Group. Neurology. 1990;40(6):971\u20135.","journal-title":"Neurology"},{"key":"407_CR106","first-page":"555","volume":"8","author":"L Nuzzo di","year":"2014","unstructured":"di Nuzzo L, Orlando R, Nasca C, Nicoletti F. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Design Develop Ther. 2014;8:555\u201368.","journal-title":"Drug Design Develop Ther"},{"issue":"13","key":"407_CR107","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2174\/1389450115666141029234644","volume":"15","author":"M Bonnan","year":"2014","unstructured":"Bonnan M, Ferrari S, Bertandeau E, et al. Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials. Curr Drug Targets. 2014;15(13):1205\u201314.","journal-title":"Curr Drug Targets"},{"issue":"2","key":"407_CR108","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.neuron.2015.09.036","volume":"88","author":"N Bien-Ly","year":"2015","unstructured":"Bien-Ly N, Boswell CA, Jeet S, et al. Lack of widespread BBB disruption in Alzheimer\u2019s disease models: focus on therapeutic antibodies. Neuron. 2015;88(2):289\u201397.","journal-title":"Neuron"},{"issue":"2","key":"407_CR109","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1124\/jpet.111.183483","volume":"339","author":"RB Pepinsky","year":"2011","unstructured":"Pepinsky RB, Shao Z, Ji B, et al. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J Pharmacol Exp Ther. 2011;339(2):519\u201329.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"407_CR110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458508098268","volume":"15","author":"HF Petereit","year":"2009","unstructured":"Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler. 2009;15(2):189\u201392.","journal-title":"Mult Scler"},{"issue":"(Meeting Abstra","key":"407_CR111","first-page":"P02.021","volume":"78","author":"J Tran","year":"2012","unstructured":"Tran J, Palaparthy R, Zhao J, et al. Safety, tolerability and pharmacokinetics of the anti-LINGO-1 monoclonal antibody BIIB033 in healthy volunteers and subjects with multiple sclerosis. Neurology. 2012;78((Meeting Abstracts 1)):P02.021.","journal-title":"Neurology"},{"key":"407_CR112","unstructured":"Greenberg BM, Rodriguez M, Kantarci O, et al. Safety and tolerability of the remyelinating therapeutic antibody rHIgM22 in patients with stable multiple sclerosis. Neurology. 2015:E48\u2013E49."},{"key":"407_CR113","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.nbd.2013.01.011","volume":"54","author":"R Willi","year":"2013","unstructured":"Willi R, Schwab ME. Nogo and Nogo receptor: relevance to schizophrenia? Neurobiol Dis. 2013;54:150\u20137.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"407_CR114","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1086\/376549","volume":"73","author":"CM Lewis","year":"2003","unstructured":"Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet. 2003;73(1):34\u201348.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"407_CR115","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1523\/JNEUROSCI.4393-09.2010","volume":"30","author":"R Willi","year":"2010","unstructured":"Willi R, Weinmann O, Winter C, et al. Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes. J Neurosci. 2010;30(2):556\u201367.","journal-title":"J Neurosci"},{"issue":"49","key":"407_CR116","doi-asserted-by":"crossref","first-page":"13161","DOI":"10.1523\/JNEUROSCI.3828-08.2008","volume":"28","author":"S Budel","year":"2008","unstructured":"Budel S, Padukkavidana T, Liu BP, et al. Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J Neurosci. 2008;28(49):13161\u201372.","journal-title":"J Neurosci"},{"key":"407_CR117","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.expneurol.2013.09.015","volume":"250","author":"LM Craveiro","year":"2013","unstructured":"Craveiro LM, Weinmann O, Roschitzki B, et al. Infusion of anti-Nogo-A antibodies in adult rats increases growth and synapse related proteins in the absence of behavioral alterations. Exp Neurol. 2013;250:52\u201368.","journal-title":"Exp Neurol"},{"issue":"13","key":"407_CR118","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1523\/JNEUROSCI.23-13-05393.2003","volume":"23","author":"T Oertle","year":"2003","unstructured":"Oertle T, van der Haar ME, Bandtlow CE, et al. Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. J Neurosci. 2003;23(13):5393\u2013406.","journal-title":"J Neurosci"},{"issue":"6255","key":"407_CR119","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/343269a0","volume":"343","author":"L Schnell","year":"1990","unstructured":"Schnell L, Schwab ME. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature. 1990;343(6255):269\u201372.","journal-title":"Nature"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0407-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-017-0407-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0407-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T22:45:03Z","timestamp":1719009903000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-017-0407-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,19]]},"references-count":119,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["407"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0407-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,19]]}}}